companydata.dkcompanydata.dk

BIOMOTION PHARMA ApS: Financial statements 2024

CVR: 12928203

Source: annual report 2024, Danish Business Authority

01/10/2023 – 30/09/2024

BIOMOTION PHARMA ApS (CVR 12928203) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -5,313 and a net result of DKK -6,460 compared with DKK -1,430 the year before. Equity in the 2024 report amounted to DKK 3,310. The solvency ratio was 42.4%.

Gross Profit
DKK -5,313
Profit/Loss
DKK -6,460
Equity
DKK 3,310
Total Assets
DKK 7,801

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--5 t.-6 t.3 t.-
20230-1 t.-1 t.10 t.-
202216 t.6 t.6 t.11 t.-
2021--1 t.4 t.5 t.-
2020--1 t.-1 t.1 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Michael Rasmussen joins BIOMOTION PHARMA ApS as liquidatorDec 12, 2024

As of December 12, 2024, Michael Rasmussen is registered as liquidator of BIOMOTION PHARMA ApS.

Michael Rasmussen steps down as director of BIOMOTION PHARMA ApSDec 12, 2024

As of December 12, 2024, Michael Rasmussen has stepped down as director of BIOMOTION PHARMA ApS.

BIOMOTION PHARMA ApS enters liquidationDec 12, 2024

On December 12, 2024, BIOMOTION PHARMA ApS entered liquidation.

About BIOMOTION PHARMA ApS

BIOMOTION PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 1989. The company is in liquidation. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named HANDEL OG INVESTERING AF 1989 ApS and DANSK FARMASAN A/S. The management consists of Michael Rasmussen. The company is owned by Michael Rasmussen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,000 and a net result of DKK -4,202 compared with DKK -6,460 the year before. Equity in the 2025 report amounted to DKK -892.

Source: annual report 2025, Danish Business Authority